Trelegy Ellipta Approval History
FDA Approved: Yes (First approved September 18, 2017)
Brand name: Trelegy Ellipta
Generic name: fluticasone furoate, umeclidinium and vilanterol
Dosage form: Inhalation Powder
Treatment for: COPD
Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is an inhaled corticosteroid, long-acting muscarinic antagonist (LAMA) and long-acting beta2-adrenergic agonist (LABA) combination for the treatment of patients with chronic obstructive pulmonary disease (COPD).
Development History and FDA Approval Process for Trelegy Ellipta
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.